RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Sponsored by Reunion Neuroscience Inc
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Where this study is enrolling (32)
- I'm interested
UAB, Psychiatry and Behavioral Neurology
Birmingham, Alabama
- I'm interested
University of Arizona
Tucson, Arizona
- I'm interested
Kadima Neuropsychiatry Institute
San Diego, California
- I'm interested
Providence Medical Foundation
Santa Rosa, California
- I'm interested
University of Colorado
Aurora, Colorado
Show all 32 locations
- I'm interested
University of South Florida, Department of Psychiatry and Behavioral Neuroscience
Tampa, Florida
- I'm interested
Emory University
Atlanta, Georgia
- I'm interested
Hawaii Pacific Neuroscience
Honolulu, Hawaii
- I'm interested
University of Chicago Medical Center
Chicago, Illinois
- I'm interested
Rush University Medical Center
Chicago, Illinois
- I'm interested
The University of Kansas Medical Center
Kansas City, Kansas
- I'm interested
LSU Health Shreveport
Shreveport, Louisiana
- I'm interested
Sheppard Pratt
Towson, Maryland
- I'm interested
Sunstone Therapies, PC
Rockville, Maryland
- I'm interested
Dana Farber Cancer Institute
Boston, Massachusetts
- I'm interested
University of Massachusetts Chan Medical Center
Worcester, Massachusetts
- I'm interested
Henry Ford Health
Novi, Michigan
- I'm interested
University of Michigan
Ann Arbor, Michigan
- I'm interested
University of Nebraska Medical Center
Omaha, Nebraska
- I'm interested
University of New Mexico, School of Medicine
Albuquerque, New Mexico
- I'm interested
Roswell Park Center Institute
Buffalo, New York
- I'm interested
NYU Langone Health
New York, New York
- I'm interested
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
- I'm interested
The Ohio State University, Department of Psychiatry
Columbus, Ohio
- I'm interested
Cleveland Clinic
Cleveland, Ohio
- I'm interested
University of Pennsylvania
Philadelphia, Pennsylvania
- I'm interested
Alliance for Multispecialty Research Clinical
Knoxville, Tennessee
- I'm interested
Dell Medical School, University of Texas at Austin
Austin, Texas
- I'm interested
Cedar Clinical Research Inc.
Draper, Utah
- I'm interested
UVA Center for Psychiatric Clinical Research
Charlottesville, Virginia
- I'm interested
Seattle Neuropsychiatric Treatment Center
Seattle, Washington
- I'm interested
University of Wisconsin at Madison
Madison, Wisconsin
Who can participate
Inclusion criteria
- ✓Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF
- ✓Is sufficiently ambulatory and capable of self care as necessary to complete study procedures
- ✓Has normal cognitive function
- ✓Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study
- ✓If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant
- ✓Is willing and able to comply with the conditions and requirements of the study
Exclusion criteria
- ✕Has a significant risk of suicide
- ✕Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- ✕Has active or a history of central nervous system malignancy
- ✕Has other medically significant conditions rendering unsuitability for the study
- ✕Has used or will need to use prohibited medications or therapies
- ✕Has a known sensitivity or intolerance to study intervention or potential rescue medications
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.